Prostate Specialized Programs of Research Excellence
Reducing morbidity & mortality of prostate cancer
Since its inception in 1995, the Michigan Prostate SPORE has harnessed the extensive intellectual and physical resources of the University of Michigan (U-M) community to reduce the morbidity and mortality associated with prostate cancer. The program supports an interactive group of basic and clinical investigators engaged in translational research, leading to significant advancements in the diagnosis, prevention, and treatment of prostate cancer. These translational research efforts are bolstered by horizontal and vertical collaborations with numerous institutions, resources, and biotech companies.
Prostate SPORE Principal Investigators
Arul Chinnaiyan, MD, PhD
Section Head
Michigan Center for Translational Pathology
Professor of Pathology and Professor of Urology
Medical School
Ganesh S Palapattu, MD, FACS, FRCS(Glasg)
Department of Urology
Medical School
The current Michigan SPORE consists of three projects
- Project 1: Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in neuroendocrine prostate cancer.
- Project 2: Validation and clinical utility of a multiplex urine biomarker for identification of clinically significant prostate cancer.
- Project 3: Development of serine/threonine phosphatase PP2A molecular glues for the treatment of advanced prostate cancer.
These projects are supported by ongoing institutional commitment of funding and space, successful Career Enhancement and Developmental Research Programs, and three cores:
The Michigan Prostate SPORE continues to prioritize rigorous scientific review of its translational research programs, the collaboration of basic and clinical investigators, leveraging expertise from within and outside the prostate cancer field, and maintaining flexibility to fund promising new research approaches. The Michigan Prostate SPORE has a long history of success and has been instrumental in many landmark discoveries that have changed the clinical management of prostate cancer patients. Our strong multidisciplinary program will ensure the successful completion of our proposed aims for each project and core.
